Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Hsp70-peptide TKD/IL-2-activated autologous natural killer cells

A preparation of autologous natural killer (NK) cells that are stimulated ex vivo by a 14-mer heat shock protein 70 (Hsp70) TKD peptide and interleukin-2 (IL-2), with potential tumor-selective cytolytic activity. Upon re-infusion into the patient, the treated NK cells recognize and bind to Hsp70-expressing tumor cells, which induces NK-mediated tumor cell lysis. Hsp70, a membrane-bound, stress-inducible protein, is overexpressed on almost all tumor cells; however, it is absent or minimally present on normal, healthy cells. TKD is the C-terminal substrate-binding domain of Hsp70 and is the structure recognized by the activated NK cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Hsp70-peptide TKD/IL-2-activated autologous NK cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search